![Thomas Mehrling](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Thomas Mehrling
Algemeen Directeur bij
HELIX BIOPHARMA CORP.
Vermogen: 50 290 $ op 31-07-2026
Profiel
Thomas J.
Mehrling is the founder of Laevoroc Oncology AG, founded in 2019, where Dr. Mehrling holds the title of Chief Executive Officer.
Dr. Mehrling was the founder of Mundipharma EDO GmbH, founded in 2013, where Dr. Mehrling held the title of Chief Executive Officer.
Dr. Mehrling is also the founder of Laevoroc Immunology AG..
Dr. Mehrling is Chief Executive Officer at Release Therapeutics SA since 2024.
Dr. Mehrling is Chief Executive Officer at Helix BioPharma Corp.
starting in 2025.
Dr. Mehrling is Chairman & Chief Executive Officer at Laevoroc Chemotherapy AG.
Dr. Mehrling was Managing Director-European Oncology at Mundipharma International Ltd. from 2003 to 2013.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
| 21-05-2026 | 47.000 ( 0,06% ) | 50 290 $ | 31-07-2026 |
Actieve functies van Thomas Mehrling
| Bedrijven | Functie | Begin |
|---|---|---|
| HELIX BIOPHARMA CORP. | Algemeen Directeur | 10-04-2025 |
Laevoroc Oncology AG
 Laevoroc Oncology AG BiotechnologyHealth Technology Develops and manufactures cancer immunotherapies | Algemeen Directeur | 01-02-2019 |
Release Therapeutics SA
 Release Therapeutics SA BiotechnologyHealth Technology Develops first cell microencapsulation technology to deliver therapeutic proteins beyond the human blood-brain barrier | Algemeen Directeur | 27-06-2024 |
Eerdere bekende functies van Thomas Mehrling
| Bedrijven | Functie | Einde |
|---|---|---|
Mundipharma EDO GmbH
 Mundipharma EDO GmbH Miscellaneous Commercial ServicesCommercial Services Engages in research and development of therapies for cancer | Algemeen Directeur | 01-07-2019 |
Mundipharma International Ltd.
 Mundipharma International Ltd. Pharmaceuticals: MajorHealth Technology Develops and produces pharmaceutical products | Corporate Officer/Principal | 01-01-2013 |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
23
Eerstegraads connecties
5
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Bedrijven in privébezit | 5 |
|---|---|
Helix BioPharma Corp.
 Helix BioPharma Corp. Pharmaceuticals: MajorHealth Technology Develops drugs for the prevention and treatment of cancer | Health Technology |
Mundipharma International Ltd.
Mundipharma International Ltd. Pharmaceuticals: MajorHealth Technology Develops and produces pharmaceutical products | Health Technology |
Release Therapeutics SA
Release Therapeutics SA BiotechnologyHealth Technology Develops first cell microencapsulation technology to deliver therapeutic proteins beyond the human blood-brain barrier | Health Technology |
Mundipharma EDO GmbH
Mundipharma EDO GmbH Miscellaneous Commercial ServicesCommercial Services Engages in research and development of therapies for cancer | Commercial Services |
Laevoroc Oncology AG
Laevoroc Oncology AG BiotechnologyHealth Technology Develops and manufactures cancer immunotherapies | Health Technology |
